Reich & Binstock
Free Initial Consultation Call
713-352-7883
713-352-7883

Posts tagged "Gynecomastia"

Pill Popping Nation: Let Children be Children

It was once expected that children would be playful, adventurous and boisterous. We used to have sayings like "boys will be boys," or "let her be a kid." Nowadays, though, an active child is said to be "disordered" or "mentally ill." They are given labels like ADHD or bipolar and put on dangerous prescription and harsh antipsychotic drugs like Risperdal.

Pill Popping Nation: Let Children be Children

It was once expected that children would be playful, adventurous and boisterous. We used to have sayings like "boys will be boys," or "let her be a kid." Nowadays, though, an active child is said to be "disordered" or "mentally ill." They are given labels like ADHD or bipolar and put on dangerous prescription and harsh antipsychotic drugs like Risperdal.

Risperdal company owes South Carolina $124 million

It appears that Janssen Pharmaceuticals and other defendants behind the manufacture and marketing of the antipsychotic drug Risperdal (risperidone) owe the state of South Carolina $124 million. The U.S. Supreme Court on Jan. 11 refused to review Janssen's appeal of a $124 million civil penalty that the state imposed for not disclosing the drug's risks, notably the risk of the enlargement of male breasts, a condition known as gynecomastia.

Risperdal company owes South Carolina $124 million

It appears that Janssen Pharmaceuticals and other defendants behind the manufacture and marketing of the antipsychotic drug Risperdal (risperidone) owe the state of South Carolina $124 million. The U.S. Supreme Court on Jan. 11 refused to review Janssen's appeal of a $124 million civil penalty that the state imposed for not disclosing the drug's risks, notably the risk of the enlargement of male breasts, a condition known as gynecomastia.

Federal court's drug marketing ruling a Risperdal reminder

An Aug. 7 ruling by a federal district court in New York raised the issue of whether a drug company is culpable of "misbranding" a drug, in violation of federal regulations, when the company markets the drug for a purpose unapproved by the U.S. Food and Drug Administration. The case did not address in any way U.S. Justice Department and FDA proceedings in regard to the antipsychotic Risperdal, but it did address the broader issue of how far a drug company can go in the so-called "off-label" marketing of its product.

Federal court's drug marketing ruling a Risperdal reminder

An Aug. 7 ruling by a federal district court in New York raised the issue of whether a drug company is culpable of "misbranding" a drug, in violation of federal regulations, when the company markets the drug for a purpose unapproved by the U.S. Food and Drug Administration. The case did not address in any way U.S. Justice Department and FDA proceedings in regard to the antipsychotic Risperdal, but it did address the broader issue of how far a drug company can go in the so-called "off-label" marketing of its product.

Risperdal lawsuits from states move forward

Trial has been scheduled for April 2016 in the state of Kentucky's complaint against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., in regard to the corporations' alleged misbranded promotion of the antipsychotic drug Risperdal (risperidone). J&J reported the trial timeline in its most recent quarterly report to the U.S. Securities and Exchange Commission.

Risperdal lawsuits from states move forward

Trial has been scheduled for April 2016 in the state of Kentucky's complaint against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., in regard to the corporations' alleged misbranded promotion of the antipsychotic drug Risperdal (risperidone). J&J reported the trial timeline in its most recent quarterly report to the U.S. Securities and Exchange Commission.

Risperdal settlement occurs amid growing litigation

Risperdal lawsuits continue to be filed in regard to the antipsychotic drug's side effects to male patients. Meanwhile, several defendants, including Janssen Pharmaceuticals, the manufacturer of Risperdal (risperidone), agreed May 18 to pay the State of Arkansas nearly $7.8 million to settle litigation in regard to the marketing of the drug. The agreement is contained in a May 18 order handed down by the state's Sixth Division Circuit Court of Pulaski County.

Risperdal settlement occurs amid growing litigation

Risperdal lawsuits continue to be filed in regard to the antipsychotic drug's side effects to male patients. Meanwhile, several defendants, including Janssen Pharmaceuticals, the manufacturer of Risperdal (risperidone), agreed May 18 to pay the State of Arkansas nearly $7.8 million to settle litigation in regard to the marketing of the drug. The agreement is contained in a May 18 order handed down by the state's Sixth Division Circuit Court of Pulaski County.

Email Us For A Response

Contact Us For a Free Legal Consultation There is a never a fee unless we recover on your behalf.

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Call for a Free Legal Consultation: 713-352-7883
Reich & Binstock - Pharmaceutical Injury & Class Action Lawyers

4265 San Felipe
Suite 1000
Houston, TX 77027

Toll Free: 877-643-3099
Phone: 713-352-7883
Fax: 713-623-8724
Houston Law Office Map